Nintedanib Accordpharma

Nintedanib, the active ingredient in Nintedanib Accordpharma, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer.

GNH USA supplies Nintedanib Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, specialty clinics and pharmacies worldwide, with support for regulatory and logistics requirements and ensuring timely delivery across regions.

Nintedanib is used to target fibrotic lung disease pathways and certain oncologic indications. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when combined with standard chemotherapy.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent, often mild to moderate. - Nausea and vomiting: may affect appetite. - Abdominal pain: occasional discomfort. - Decreased appetite: reduced food intake. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury. - Major bleeding: gastrointestinal or intracranial hemorrhage. - Arterial thromboembolism: risk of clot formation. - Severe hypertension: marked blood pressure increase. - Gastrointestinal perforation: rare but life‑threatening.

Before initiating therapy, clinicians should consider several safety measures. - Liver function monitoring: assess hepatic enzymes before and during treatment. - Bleeding risk: avoid in patients with active bleeding or on anticoagulants. - Cardiovascular assessment: monitor blood pressure regularly. - Gastrointestinal health: watch for severe diarrhea or abdominal pain. - Pregnancy and lactation: use only if potential benefit justifies risk; safety not established. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure. - Anticoagulants: heightened bleeding risk. - High‑dose aspirin or NSAIDs: increased gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce efficacy. - P‑glycoprotein inhibitors: may raise plasma levels. - Antihypertensive agents: possible additive blood pressure effects.